Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical studies to have activity against such tumors. METHODS: We conducted an open-label, randomized, multicenter trial to evaluate the activity of imatinib in patients with advanced gastrointestinal stromal tumor. We assessed antitumor response and the safety and tolerability of the drug. Pharmacokinetics were assessed in a subgroup of patients. RESULTS: A total of 147 patients were randomly assigned to receive 400 mg or 600 mg of imatinib daily. Overall, 79 patients (53.7 percent) had a partial response, 41 patients (27.9 percent) had stable disease, and for technical reasons, response could not be evaluated in 7 patients (4.8 percent). No patient had a complete response to the treatment. The median duration of response had not been reached after a median follow-up of 24 weeks after the onset of response. Early resistance to imatinib was noted in 20 patients (13.6 percent). Therapy was well tolerated, although mild-to-moderate edema, diarrhea, and fatigue were common. Gastrointestinal or intraabdominal hemorrhage occurred in approximately 5 percent of patients. There were no significant differences in toxic effects or response between the two doses. Imatinib was well absorbed, with pharmacokinetics similar to those reported in patients with chronic myeloid leukemia. CONCLUSIONS: Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor. Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationDiagnosis of gastrointestinal stromal tumors: A consensus approach
Fletcher, C. D. M., Berman, J. J., Corless, C., Gorstein, F., Lasota, J., Longley, B. J., Miettinen, M., O'Leary, T. J., Remotti, H., Rubin, B. P., et al. (2002) · Human Pathology · doi:10.1053/hupa.2002.123545 · Cited by 3,419
Self-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Self-citationDruker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citationTwo Hundred Gastrointestinal Stromal Tumors: Recurrence Patterns and Prognostic Factors for Survival
DeMatteo, R. P., Lewis, J. J., Leung, D., Mudan, S. S., Woodruff, J. M., & Brennan, M. F. (2000) · Annals of Surgery · doi:10.1097/00000658-200001000-00008 · Cited by 2,554
Joensuu, H., Roberts, P. J., Sarlomo-Rikala, M., Andersson, L. C., Tervahartiala, P., Tuveson, D., Silberman, S. L., Capdeville, R., Dimitrijevic, S., Druker, B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441404 · Cited by 2,037
Self-citationBuchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., & Lydon, N. B. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38879-2 · Cited by 1,274
Self-citationvan Oosterom, A. T., Judson, I., Verweij, J., Stroobants, S., di Paola, E. D., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06535-7 · Cited by 1,264
Self-citationHeinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A., & Zigler, A. J. (2000) · Blood · doi:10.1182/blood.v96.3.925 · Cited by 1,071
Self-citation
Research works printed but not linked: 4
- Rubin BP, 2001, Cancer Res, 61, 8118
- Goss GA, 2000, Prog Proc Am Soc Clin Oncol, 19, 599a
- Buchdunger E, 2000, J Pharmacol Exp Ther, 295, 139
- Peng B, 2001, Prog Proc Am Soc Clin Oncol, 20, 71a
Cited by
Items 101–200 of 1,007
Janku, F., Wheler, J. J., Westin, S. N., Moulder, S. L., Naing, A., Tsimberidou, A. M., Fu, S., Falchook, G. S., Hong, D. S., Garrido-Laguna, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1196 · Cited by 447
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Chen, Z., Cheng, K., Walton, Z., Wang, Y., Ebi, H., Shimamura, T., Liu, Y., Tupper, T., Ouyang, J., Li, J., et al. (2012) · Nature · doi:10.1038/nature10937 · Cited by 446
Self-citationRaut, C. P., Posner, M., Desai, J., Morgan, J. A., George, S., Zahrieh, D., Fletcher, C. D. M., Demetri, G. D., & Bertagnolli, M. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3439 · Cited by 448
Self-citationClinical management of uterine sarcomas
Amant, F., Coosemans, A., Debiec-Rychter, M., Timmerman, D., & Vergote, I. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70226-8 · Cited by 443
Mosele, M. F., Westphalen, C. B., Stenzinger, A., Barlesi, F., Bayle, A., Bièche, I., Bonastre, J., Castro, E., Dienstmann, R., Krämer, A., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.04.005 · Cited by 415
Debiec-Rychter, M., Dumez, H., Judson, I., Wasag, B., Verweij, J., Brown, M., Dimitrijevic, S., Sciot, R., Stul, M., Vranck, H., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.11.025 · Cited by 444
Miettinen, M., Wang, Z.-F., & Lasota, J. (2009) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181a90e1a · Cited by 432
Espinosa, I., Lee, C.-H., Kim, M. K., Rouse, B.-T., Subramanian, S., Montgomery, K., Varma, S., Corless, C. L., Heinrich, M. C., Smith, K. S., et al. (2008) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181238cec · Cited by 433
Self-citationProfiling Critical Cancer Gene Mutations in Clinical Tumor Samples
MacConaill, L. E., Campbell, C. D., Kehoe, S. M., Bass, A. J., Hatton, C., Niu, L., Davis, M., Yao, K., Hanna, M., Mondal, C., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007887 · Cited by 438
Self-citationCohen, M. H., Farrell, A., Justice, R., & Pazdur, R. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0255 · Cited by 426
Eisenberg, B. L., Harris, J., Blanke, C. D., Demetri, G. D., Heinrich, M. C., Watson, J. C., Hoffman, J. P., Okuno, S., Kane, J. M., & von Mehren, M. (2009) · Journal of Surgical Oncology · doi:10.1002/jso.21160 · Cited by 427
Self-citationWen, P. Y., Yung, W. K. A., Lamborn, K. R., Dahia, P. L., Wang, Y., Peng, B., Abrey, L. E., Raizer, J., Cloughesy, T. F., Fink, K., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0773 · Cited by 429
Self-citationAnaplastic lymphoma kinase: signalling in development and disease
Palmer, R. H., Vernersson, E., Grabbe, C., & Hallberg, B. (2009) · Biochemical Journal · doi:10.1042/bj20090387 · Cited by 423
Major Response to Imatinib Mesylate in KIT-Mutated Melanoma
Hodi, F. S., Friedlander, P., Corless, C. L., Heinrich, M. C., Mac Rae, S., Kruse, A., Jagannathan, J., Van den Abbeele, A. D., Velazquez, E. F., Demetri, G. D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0707 · Cited by 419
Self-citationChaft, J. E., Oxnard, G. R., Sima, C. S., Kris, M. G., Miller, V. A., & Riely, G. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1468 · Cited by 418
Burger, H., van Tol, H., Boersma, A. W. M., Brok, M., Wiemer, E. A. C., Stoter, G., & Nooter, K. (2004) · Blood · doi:10.1182/blood-2004-04-1398 · Cited by 417
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Llovet, J. M., Villanueva, A., Marrero, J. A., Schwartz, M., Meyer, T., Galle, P. R., Lencioni, R., Greten, T. F., Kudo, M., Mandrekar, S. J., et al. (2021) · Hepatology · doi:10.1002/hep.31327 · Cited by 413
Suppression of BRAF(V599E) in human melanoma abrogates transformation.
Hingorani, S. R., Jacobetz, M. A., Robertson, G. P., Herlyn, M., & Tuveson, D. A. (2003) · PubMed · Cited by 455
Self-citationAccelerating Discovery of Functional Mutant Alleles in Cancer
Chang, M. T., Bhattarai, T. S., Schram, A. M., Bielski, C. M., Donoghue, M. T. A., Jonsson, P., Chakravarty, D., Phillips, S., Kandoth, C., Penson, A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0321 · Cited by 409
Verweij, J., van Oosterom, A., Blay, J.-Y., Judson, I., Rodenhuis, S., van der Graaf, W., Radford, J., Le Cesne, A., Hogendoorn, P. C. W., di Paola, E. D., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00836-5 · Cited by 404
Demetri, G. D., Wang, Y., Wehrle, E., Racine, A., Nikolova, Z., Blanke, C. D., Joensuu, H., & von Mehren, M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.4818 · Cited by 401
Self-citationPractical Management of Patients With Chronic Myeloid Leukemia Receiving Imatinib
Deininger, M. W. N., O’Brien, S. G., Ford, J. M., & Druker, B. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.143 · Cited by 402
Self-citationArmstrong, S. A., Kung, A. L., Mabon, M. E., Silverman, L. B., Stam, R. W., Den Boer, M. L., Pieters, R., Kersey, J. H., Sallan, S. E., Fletcher, J. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00003-5 · Cited by 398
Self-citationGajiwala, K. S., Wu, J. C., Christensen, J., Deshmukh, G. D., Diehl, W., DiNitto, J. P., English, J. M., Greig, M. J., He, Y.-A., Jacques, S. L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812413106 · Cited by 391
Self-citationBlay, J.-Y., Le Cesne, A., Ray-Coquard, I., Bui, B., Duffaud, F., Delbaldo, C., Adenis, A., Viens, P., Rios, M., Bompas, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0183 · Cited by 392
Rutkowski, P., Van Glabbeke, M., Rankin, C. J., Ruka, W., Rubin, B. P., Debiec-Rychter, M., Lazar, A., Gelderblom, H., Sciot, R., Lopez-Terrada, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7899 · Cited by 398
Pardanani, A., Ketterling, R. P., Brockman, S. R., Flynn, H. C., Paternoster, S. F., Shearer, B. M., Reeder, T. L., Li, C.-Y., Cross, N. C. P., Cools, J., et al. (2003) · Blood · doi:10.1182/blood-2003-05-1627 · Cited by 393
Miettinen, M., Kopczynski, J., Makhlouf, H. R., Sarlomo-Rikala, M., Gyorffy, H., Burke, A., Sobin, L. H., & Lasota, J. (2003) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200305000-00006 · Cited by 391
Novel V600E BRAF mutations in imatinib‐naive and imatinib‐resistant gastrointestinal stromal tumors
Agaram, N. P., Wong, G. C., Guo, T., Maki, R. G., Singer, S., DeMatteo, R. P., Besmer, P., & Antonescu, C. R. (2008) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20589 · Cited by 388
Self-citationInterstitial cells of Cajal in health and disease
Farrugia, G. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2008.01109.x · Cited by 383
Current clinical management of gastrointestinal stromal tumor
Akahoshi, K., Oya, M., Koga, T., & Shiratsuchi, Y. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i26.2806 · Cited by 376
Zalcberg, J. R., Verweij, J., Casali, P. G., Le Cesne, A., Reichardt, P., Blay, J.-Y., Schlemmer, M., Van Glabbeke, M., Brown, M., & Judson, I. R. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.034 · Cited by 378
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
Sequist, L. V., Heist, R. S., Shaw, A. T., Fidias, P., Rosovsky, R., Temel, J. S., Lennes, I. T., Digumarthy, S., Waltman, B. A., Bast, E., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr489 · Cited by 370
“Employing genotype-based therapy has been highly successful in chronic myelogenous leukemia, gastrointestinal stromal tumors, nonsmall-cell lung cancer (NSCLC) and melanoma, and in many instances, the targeted agent is far more effective than traditional chemotherapy [1–9].”
Autocrine Factors That Sustain Glioma Invasion and Paracrine Biology in the Brain Microenvironment
Hoelzinger, D. B., Demuth, T., & Berens, M. E. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm187 · Cited by 372
Imatinib as a Paradigm of Targeted Therapies
(2004) · Advances in Cancer Research · doi:10.1016/s0065-230x(04)91001-9 · Cited by 370
Self-citationDrug interactions in cancer therapy
Scripture, C. D., & Figg, W. D. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1887 · Cited by 366
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias
Gambacorti-Passerini, C. B., Gunby, R. H., Piazza, R., Galietta, A., Rostagno, R., & Scapozza, L. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)00979-3 · Cited by 373
Cassier, P. A., Italiano, A., Gomez-Roca, C. A., Le Tourneau, C., Toulmonde, M., Cannarile, M. A., Ries, C., Brillouet, A., Müller, C., Jegg, A.-M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00132-1 · Cited by 364
Mazières, J., Zalcman, G., Crinò, L., Biondani, P., Barlesi, F., Filleron, T., Dingemans, A.-M. C., Léna, H., Monnet, I., Rothschild, S. I., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3302 · Cited by 369
Druker, B. J., O’Brien, S. G., Cortes, J., & Radich, J. (2002) · Hematology · doi:10.1182/asheducation-2002.1.111 · Cited by 62
Self-citationMolecular Genetics of Acute Lymphoblastic Leukemia
Armstrong, S. A., & Look, A. T. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.047 · Cited by 362
Tryggvason, G., Gíslason, H. G., Magnússon, M. K., & Jónasson, J. G. (2005) · International Journal of Cancer · doi:10.1002/ijc.21167 · Cited by 358
RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors
de Groot, J. W. B., Links, T. P., Plukker, J. T. M., Lips, C. J. M., & Hofstra, R. M. W. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0017 · Cited by 356
Gastrointestinal stromal tumours
Connolly, E. M., Gaffney, E., & Reynolds, J. V. (2003) · British Journal of Surgery · doi:10.1002/bjs.4352 · Cited by 354
Breedveld, P., Pluim, D., Cipriani, G., Wielinga, P., van Tellingen, O., Schinkel, A. H., & Schellens, J. H. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2416 · Cited by 351
Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version
Nishida, T., Hirota, S., Yanagisawa, A., Sugino, Y., Minami, M., Yamamura, Y., Otani, Y., Shimada, Y., Takahashi, F., & Kubota, T. (2008) · International Journal of Clinical Oncology · doi:10.1007/s10147-008-0798-7 · Cited by 353
Lineage dependency and lineage-survival oncogenes in human cancer
Garraway, L. A., & Sellers, W. R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1947 · Cited by 360
Prognostic versus predictive value of biomarkers in oncology
Oldenhuis, C. N. A. M., Oosting, S. F., Gietema, J. A., & de Vries, E. G. E. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.03.006 · Cited by 349
Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
Gainor, J. F., & Shaw, A. T. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2029 · Cited by 346
Friedman, S. L. (2008) · Toxicology · doi:10.1016/j.tox.2008.06.013 · Cited by 350
Philadelphia ChromosomePositive Leukemias: From Basic Mechanisms to Molecular Therapeutics
Kurzrock, R., Kantarjian, H. M., Druker, B. J., & Talpaz, M. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-10-200305200-00010 · Cited by 345
Self-citationMechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)
Duensing, A., Medeiros, F., McConarty, B., Joseph, N. E., Panigrahy, D., Singer, S., Fletcher, C. D., Demetri, G. D., & Fletcher, J. A. (2004) · Oncogene · doi:10.1038/sj.onc.1207525 · Cited by 343
Self-citationDrug-sensitive FGFR2 mutations in endometrial carcinoma
Dutt, A., Salvesen, H. B., Chen, T.-H., Ramos, A. H., Onofrio, R. C., Hatton, C., Nicoletti, R., Winckler, W., Grewal, R., Hanna, M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803379105 · Cited by 345
Zhang, P., Gao, W., Turner, S., & Ducatman, B. S. (2003) · Molecular Cancer · doi:10.1186/1476-4598-2-1 · Cited by 344
Personalized medicine in oncology: the future is now
Schilsky, R. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3181 · Cited by 337
Use of PET for monitoring cancer therapy and for predicting outcome.
Weber, W. (2005) · PubMed · Cited by 341
Chen, L. L., Trent, J. C., Wu, E. F., Fuller, G. N., Ramdas, L., Zhang, W., Raymond, A. K., Prieto, V. G., Oyedeji, C. O., Hunt, K. K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0085 · Cited by 339
Olmos, D., Postel-Vinay, S., Molife, L. R., Okuno, S. H., Schuetze, S. M., Paccagnella, M. L., Batzel, G. N., Yin, D., Pritchard-Jones, K., Judson, I., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70354-7 · Cited by 340
Mross, K., Frost, A., Steinbild, S., Hedbom, S., Büchert, M., Fasol, U., Unger, C., Krätzschmar, J., Heinig, R., Boix, O., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1900 · Cited by 335
Biology of Platelet-Derived Growth Factor and Its Involvement in Disease
Alvarez, R. H., Kantarjian, H. M., & Cortes, J. E. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.9.1241 · Cited by 334
Strategies to overcome resistance to targeted protein kinase inhibitors
Daub, H., Specht, K., & Ullrich, A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1579 · Cited by 334
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
Janku, F., Tsimberidou, A. M., Garrido-Laguna, I., Wang, X., Luthra, R., Hong, D. S., Naing, A., Falchook, G. S., Moroney, J. W., Piha-Paul, S. A., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0994 · Cited by 331
Sequist, L. V., Gettinger, S., Senzer, N. N., Martins, R. G., Jänne, P. A., Lilenbaum, R., Gray, J. E., Iafrate, A. J., Katayama, R., Hafeez, N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8338 · Cited by 330
Azad, N. S., Posadas, E. M., Kwitkowski, V. E., Steinberg, S. M., Jain, L., Annunziata, C. M., Minasian, L., Sarosy, G., Kotz, H. L., Premkumar, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8332 · Cited by 332
Reardon, D. A., Egorin, M. J., Quinn, J. A., Rich, J. N., Gururangan, I., Vredenburgh, J. J., Desjardins, A., Sathornsumetee, S., Provenzale, J. M., Herndon, J. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2185 · Cited by 330
Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways
Yap, T. A., Omlin, A., & de Bono, J. S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.6418 · Cited by 329
Tamborini, E., Bonadiman, L., Greco, A., Albertini, V., Negri, T., Gronchi, A., Bertulli, R., Colecchia, M., Casali, P. G., Pierotti, M. A., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.021 · Cited by 324
Molecularly targeted therapy for malignant glioma
Sathornsumetee, S., Reardon, D. A., Desjardins, A., Quinn, J. A., Vredenburgh, J. J., & Rich, J. N. (2007) · Cancer · doi:10.1002/cncr.22741 · Cited by 325
Pathogenesis of Idiosyncratic Drug-Induced Liver Injury and Clinical Perspectives
Fontana, R. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.12.032 · Cited by 313
KIT Mutations Are Common in Testicular Seminomas
Kemmer, K., Corless, C. L., Fletcher, J. A., McGreevey, L., Haley, A., Griffith, D., Cummings, O. W., Wait, C., Town, A., & Heinrich, M. C. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63120-3 · Cited by 322
Self-citationGeorge, S., Merriam, P., Maki, R. G., Van den Abbeele, A. D., Yap, J. T., Akhurst, T., Harmon, D. C., Bhuchar, G., O'Mara, M. M., D'Adamo, D. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9890 · Cited by 321
Self-citationVI, J. G. T., Cheuk, A. T., Tsang, P. S., Chung, J.-Y., Song, Y. K., Desai, K., Yu, Y., Chen, Q.-R., Shah, K., Youngblood, V., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39703 · Cited by 321
Lasota, J., Dansonka-Mieszkowska, A., Sobin, L. H., & Miettinen, M. (2004) · Laboratory Investigation · doi:10.1038/labinvest.3700122 · Cited by 317
Heinrich, M. C., McArthur, G. A., Demetri, G. D., Joensuu, H., Bono, P., Herrmann, R., Hirte, H., Cresta, S., Koslin, D. B., Corless, C. L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0717 · Cited by 318
Self-citationDeMatteo, R. P., Maki, R. G., Singer, S., Gonen, M., Brennan, M. F., & Antonescu, C. R. (2007) · Annals of Surgery · doi:10.1097/01.sla.0000236630.93587.59 · Cited by 314
Self-citationCorless, C. L., Ballman, K. V., Antonescu, C. R., Kolesnikova, V., Maki, R. G., Pisters, P. W. T., Blackstein, M. E., Blanke, C. D., Demetri, G. D., Heinrich, M. C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.2046 · Cited by 315
Self-citationMiettinen, M., & Lasota, J. P. (2003) · PubMed · Cited by 379
Gastrointestinal stromal tumor (GIST)
Joensuu, H. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl274 · Cited by 309
Self-citationPositron Emission Tomography As an Imaging Biomarker
Weber, W. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.6068 · Cited by 312
Tissue-specific tumorigenesis: context matters
Schneider, G., Schmidt-Supprian, M., Rad, R., & Saur, D. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.5 · Cited by 311
A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain
Levinson, N. M., Kuchment, O., Shen, K., Young, M. A., Koldobskiy, M., Karplus, M., Cole, P. A., & Kuriyan, J. (2006) · PLoS Biology · doi:10.1371/journal.pbio.0040144 · Cited by 309
Gastrointestinal Stromal Tumors
von Mehren, M., & Joensuu, H. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.9705 · Cited by 306
Self-citationRecent Advances in the Treatment of Malignant Astrocytoma
Reardon, D. A., Rich, J. N., Friedman, H. S., & Bigner, D. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5302 · Cited by 307
Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors
Rusakiewicz, S., Semeraro, M., Sarabi, M., Desbois, M., Locher, C., Mendez, R., Vimond, N., Concha, A., Garrido, F., Isambert, N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0371 · Cited by 305
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
Jänne, P. A., Gray, N., & Settleman, J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2871 · Cited by 303
Borg, C., Terme, M., Taïeb, J., Ménard, C., Flament, C., Robert, C., Maruyama, K., Wakasugi, H., Angevin, E., Thielemans, K., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21102 · Cited by 302
“Gleevec administration results in objective (partial or complete) response or stabilization in about 80% of GIST patients (6).”
BackgroundSelf-citationCrizotinib-induced immunogenic cell death in non-small cell lung cancer
Liu, P., Zhao, L., Pol, J., Levesque, S., Petrazzuolo, A., Pfirschke, C., Engblom, C., Rickelt, S., Yamazaki, T., Iribarren, K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09415-3 · Cited by 302
Integration of EGFR inhibitors with radiochemotherapy
Nyati, M. K., Morgan, M. A., Feng, F. Y., & Lawrence, T. S. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1953 · Cited by 304
The genetics of malignant melanoma: lessons from mouse and man
Chin, L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1145 · Cited by 302
Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology
von Mehren, M., Randall, R. L., Benjamin, R. S., Boles, S., Bui, M. M., Conrad, E. U., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0078 · Cited by 297
Receptor Tyrosine Kinase-Targeted Cancer Therapy
Yamaoka, T., Kusumoto, S., Ando, K., Ohba, M., & Ohmori, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113491 · Cited by 297
Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma
Lin, W. M., Baker, A. C., Beroukhim, R., Winckler, W., Feng, W., Marmion, J. M., Laine, E., Greulich, H., Tseng, H., Gates, C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2615 · Cited by 297
Mir, S. E., De Witt Hamer, P. C., Krawczyk, P. M., Balaj, L., Claes, A., Niers, J. M., Van Tilborg, A. A. G., Zwinderman, A. H., Geerts, D., Kaspers, G. J. L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.011 · Cited by 294
Genomics and the Continuum of Cancer Care
McDermott, U., Downing, J. R., & Stratton, M. R. (2011) · New England Journal of Medicine · doi:10.1056/nejmra0907178 · Cited by 299
KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs)
Lasota, J., & Miettinen, M. (2006) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2006.08.006 · Cited by 291
Le Cesne, A., Ray-Coquard, I., Bui, B. N., Adenis, A., Rios, M., Bertucci, F., Duffaud, F., Chevreau, C., Cupissol, D., Cioffi, A., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70222-9 · Cited by 294
Seggewiss, R. (2005) · Blood · doi:10.1182/blood-2004-07-2527 · Cited by 290
Incidence of gastrointestinal stromal tumours is underestimated: Results of a nation-wide study
Goettsch, W. G., Bos, S. D., Breekveldt-Postma, N., Casparie, M., Herings, R. M. C., & Hogendoorn, P. C. W. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.09.009 · Cited by 291
Trudel, S., Li, Z. H., Wei, E., Wiesmann, M., Chang, H., Chen, C., Reece, D., Heise, C., & Stewart, A. K. (2005) · Blood · doi:10.1182/blood-2004-10-3913 · Cited by 289
Combined Surgical and Molecular Therapy: The Gastrointestinal Stromal Tumor Model
Gold, J. S., & DeMatteo, R. P. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000218080.94145.cf · Cited by 288
Metadata
- Authors
- Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., Fletcher, J. A., Silverman, S. G., Silberman, S. L., Capdeville, R., Kiese, B., Peng, B., Dimitrijevic, S., Druker, B. J., Corless, C., Fletcher, C. D. M., & Joensuu, H.
- Affiliations
- Harvard University (US)
- Oregon Health & Science University (US)
- Fox Chase Cancer Center (US)
- Novartis (Switzerland) (CH)
- University of Helsinki (FI)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-08-15
- Volume
- 347
- Issue
- 7
- Pages
- 472-480
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2015015957
- Cited by
- 4,389
- References
- 21
- Citations by year
- 2026: 85 · 2025: 91 · 2024: 107 · 2023: 115 · 2022: 117 · 2021: 128 · 2020: 136 · 2019: 119 · 2018: 131 · 2017: 136 · 2016: 160 · 2015: 182 · 2014: 192 · 2013: 210 · 2012: 255
- FWCI
- 167.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- CRC Press eBooks (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- U.S. Department of Veterans Affairs
- Northwest Health Foundation
- Helsingin Yliopisto
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- imatinib mesylate, gastrointestinal stromal tumor, KIT receptor tyrosine kinase, tyrosine kinase inhibitors, antitumor immunity, drug resistance, pharmacokinetics, adverse effects, metastatic cancer, dose comparison
- MeSH terms
- Imatinib Mesylate, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Benzamides, Female, Gastrointestinal Neoplasms, Humans, Male, Middle Aged, Piperazines, Protein-Tyrosine Kinases, Pyrimidines, Remission Induction, Signal Transduction, Survival Analysis, Stromal Cells, Proto-Oncogene Proteins c-kit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.